CEO-related trust at ClearPoint Neuro (CLPT) sells 19,951 shares under plan

Rhea-AI Filing Summary

ClearPoint Neuro CEO-related trust reports planned share sale

ClearPoint Neuro, Inc. director and CEO Joseph Burnett reported that a trust for which he serves as trustee sold 19,951 shares of common stock on February 25, 2026 in an open-market transaction at a weighted-average price of $15.17 per share.

The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 11, 2025. After the sale, the trust-related indirect holding stood at 193,231 shares, while Burnett’s direct ownership was 12,499 shares, reflecting a prior transfer of 934 shares from the trust on February 6, 2026.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BURNETT JOSEPH

(Last) (First) (Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH CA 92075

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/25/2026		S(1)		19,951	D	$15.17(2)	193,231(3)	I	See Footnote(4)
Common Stock								12,499(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale of shares reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1.

2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $15.15 to $15.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. Reflects 934 shares previously owned by the Joseph M. Burnett Trust dated 10/20/2022 (the "Trust") which were transferred to the Reporting Person as direct ownership on February 6, 2026.

4. These shares are owned directly by the Trust and indirectly by Joseph M. Burnett as trustee of the trust.

	/s/ Danilo D'Alessandro, by Power of Attorney for Joseph M. Burnett	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ClearPoint Neuro (CLPT) disclose in this Form 4?

ClearPoint Neuro reported that a trust associated with CEO Joseph Burnett sold 19,951 common shares on February 25, 2026. The open-market sale was executed at a weighted-average price of $15.17 per share under a pre-arranged Rule 10b5-1 trading plan.

At what prices were the ClearPoint Neuro (CLPT) shares sold in the reported trade?

The reported ClearPoint Neuro shares were sold at prices ranging from $15.15 to $15.25 per share. The Form 4 notes a weighted-average sales price of $15.17, and the insider has agreed to provide exact breakdowns of shares sold at each price upon request.

How many ClearPoint Neuro (CLPT) shares does the CEO-related trust hold after this sale?

After the February 25, 2026 sale, the trust associated with CEO Joseph Burnett held 193,231 ClearPoint Neuro common shares indirectly. These shares are owned directly by the trust and indirectly by Burnett in his capacity as trustee, according to the Form 4 footnotes.

What is Joseph Burnett’s direct ownership in ClearPoint Neuro (CLPT) after the reported transactions?

Following the reported transactions, Joseph Burnett directly owns 12,499 ClearPoint Neuro common shares. This figure includes 934 shares that were previously held by the Joseph M. Burnett Trust and were transferred into his direct ownership on February 6, 2026, as disclosed in the footnotes.

Was the ClearPoint Neuro (CLPT) insider sale part of a pre-arranged 10b5-1 plan?

Yes. The Form 4 states that the 19,951-share sale was conducted under a written trading plan adopted on June 11, 2025, in accordance with Rule 10b5-1. Such plans allow insiders to schedule trades in advance, independent of later material nonpublic information.

Who is considered the owner of the ClearPoint Neuro (CLPT) shares sold in this filing?

The shares are owned directly by the Joseph M. Burnett Trust and indirectly by Joseph Burnett as trustee. The Form 4 clarifies that the transaction reflects the trust’s holdings, with Burnett’s role tied to his position as trustee rather than purely personal ownership.